316 related articles for article (PubMed ID: 36268122)
1. Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.
Ruffilli C; Roth S; Rodrigo M; Boyd H; Zelcer N; Moreau K
ACS Pharmacol Transl Sci; 2022 Oct; 5(10):849-858. PubMed ID: 36268122
[TBL] [Abstract][Full Text] [Related]
2. Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
Li J; Chen X; Lu A; Liang C
Innovation (Camb); 2023 May; 4(3):100413. PubMed ID: 37033156
[TBL] [Abstract][Full Text] [Related]
3. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
[TBL] [Abstract][Full Text] [Related]
4. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
Tamatam R; Shin D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
[TBL] [Abstract][Full Text] [Related]
5. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
6. Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One.
Salerno A; Seghetti F; Caciolla J; Uliassi E; Testi E; Guardigni M; Roberti M; Milelli A; Bolognesi ML
J Med Chem; 2022 Jul; 65(14):9507-9530. PubMed ID: 35816671
[TBL] [Abstract][Full Text] [Related]
7. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.
Fang Y; Wang J; Zhao M; Zheng Q; Ren C; Wang Y; Zhang J
J Med Chem; 2022 Sep; 65(17):11454-11477. PubMed ID: 36006861
[TBL] [Abstract][Full Text] [Related]
8. Targeted protein degradation: A promise for undruggable proteins.
Samarasinghe KTG; Crews CM
Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187
[TBL] [Abstract][Full Text] [Related]
9. Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery.
Zeng S; Zhang H; Shen Z; Huang W
Front Chem; 2021; 9():639176. PubMed ID: 33777902
[TBL] [Abstract][Full Text] [Related]
10. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Pettersson M; Crews CM
Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
[TBL] [Abstract][Full Text] [Related]
11. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
12. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
14. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
15. A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery.
Venkatesan J; Murugan D; Rangasamy L
Antibiotics (Basel); 2022 Nov; 11(12):. PubMed ID: 36551374
[TBL] [Abstract][Full Text] [Related]
16. Nucleic-Acid-Based Targeted Degradation in Drug Discovery.
Wang W; He S; Dong G; Sheng C
J Med Chem; 2022 Aug; 65(15):10217-10232. PubMed ID: 35916496
[TBL] [Abstract][Full Text] [Related]
17. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy.
Chen X; Shen H; Shao Y; Ma Q; Niu Y; Shang Z
Transl Androl Urol; 2021 Feb; 10(2):954-962. PubMed ID: 33718095
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
19. Advancing targeted protein degradation for metabolic diseases therapy.
Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
[TBL] [Abstract][Full Text] [Related]
20. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
